KANSAS: With new $11.35M NIH COBRE award, KU Center continues fight against infectious diseases
NIH has renewed its support of the Chemical Biology of Infectious Disease Center (CBID) at the University of Kansas with a five-year, $11.35M NIGMS COBRE Phase II grant. “This Phase II award is to strengthen and expand the KU scientific community that focuses on better understanding and treatment strategies for infectious diseases with integrated chemical processes,” said P. Scott Hefty, professor of molecular biosciences, COBRE PI. “The CBID Center is intended to bridge infectious disease and medicinal chemistry expertise to better address the public health challenges.”
One of the primary goals of COBRE is to support mentoring of new faculty in obtaining external funding, Hefty said. Another goal is to improve infrastructure, primarily through supporting core research facilities.
Under the Phase II COBRE support, two new full-time faculty positions will be created in KU’s Department of Molecular Biosciences. These new faculty hires will compliment previous hires made under CBID’s Phase I funding.